streptococcal polysaccharide type III group B: Clinical Trials

7 trials of streptococcal polysaccharide type III group B, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 suspended, 1 unknown. 4 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Completed 2, Suspended 1, Unknown 1
Phase 13Completed 3

Follow streptococcal polysaccharide type III group B: new trials by email Literature Review of streptococcal polysaccharide type III group B trials Research Report on streptococcal polysaccharide type III group B

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis
10 mg/kg CM-101, Placebo - Systemic Sclerosis
Phase 2SuspendedChemomAb Ltd.452026-09-012026-04-15
A Practical RCT of TCM in the Treatment of LCOVID and Analysis of Syndrome Types and Medication Characteristics.
Traditional Chinese medicine treatment, Western medicine treatment - Long COVID
Phase 2UnknownChinese University of Hong Kong1622023-12-012023-10-26
CM-101 in NASH Patients - The SPLASH Study
5 mg/kg CM-101, Placebo - Nonalcoholic Steatohepatitis
Phase 2CompletedChemomAb Ltd.232021-02-242023-04-21
CM-101 in PSC Patients -The SPRING Study
Anti-human CCL24 monoclonal antibody (CM-101), Placebo - Primary Sclerosing Cholangitis
Phase 2CompletedChemomAb Ltd.772020-10-012026-07-02
Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
CM-101, Placebo - Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
Phase 1CompletedChemomAb Ltd.82019-03-052023-09-14
The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
Anti-human CCL24 monoclonal antibody (CM-101) - Part One, Anti-human CCL24 monoclonal antibody (CM-101) - Part Two, Placebo - Study Part One - Nonalcoholic Fatty Liver Disease
Phase 1CompletedChemomAb Ltd.162018-12-112023-09-21
Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
Anti-human CCL24 monoclonal antibody (CM-101), Placebo - Healthy
Phase 1CompletedChemomAb Ltd.322017-07-242023-09-11

Conditions studied

Non-alcoholic Fatty Liver Disease (3)  ·  Cholangitis, Sclerosing (2)  ·  Scleroderma, Systemic (2)  ·  Post-Acute COVID-19 Syndrome (1)

Sponsors

ChemomAb Ltd. (6)  ·  Chinese University of Hong Kong (1)

Countries

Israel (5)  ·  United States (2)  ·  Germany (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Matthew Frankel, MD (3)  ·  Arnon Aharon, MD (2)  ·  Hongwei Zhang, PhD (1)  ·  Jacob Atsmon, MD (1)  ·  Rifaat Safadi, MD (1)

Results publications

PMID 38822943